{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-037283","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2022-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.338238+00:00","generated_at":"2026-06-26T18:18:21.352197+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Milestone Pharma reports FY2021 net loss of $42.9M; revenue of $15M from collaboration","bullets":["Net loss for FY2021 was $42.9M ($1.02 loss per share) vs $50.0M ($1.70 loss per share) in FY2020.","Revenue of $15.0M recognized in 2021 from collaboration agreement; no revenue in 2020.","R&D expenses $38.7M, G&A $12.4M, commercial $7.0M in FY2021.","Cash and cash equivalents $114.1M at Dec 31, 2021, down from $142.3M (incl short-term investments) at Dec 31, 2020.","Accumulated deficit reached $206.3M as of Dec 31, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-037283","json":"https://secwatch.observer/filing/0001104659-22-037283.json","markdown":"https://secwatch.observer/filing/0001104659-22-037283.md","text":"https://secwatch.observer/filing/0001104659-22-037283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465922037283/0001104659-22-037283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465922037283/tm2210321d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T18:18:21.352197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}